13F Holdings
中文EN

ARGX ARGENX SE IFRS

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1697862 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY89.9%
TTM net income YoY55.1%
TTM EPS YoY53.1%
Revenue 3-yr CAGR118.0%
Net income 3-yr CAGR—

Margins

Gross margin89.1%
Operating margin25.4%
Net margin31.1%
FCF margin16.4%
EBITDA margin—

Returns

ROE20.2%
ROA17.4%
ROIC (approx.)26.9%
Asset turnover0.56x

Leverage & solvency

Liabilities / assets15.7%
Debt / equity0.00x
Current ratio5.23x
Interest coverage258.16x

Cash quality & payout

Operating cash flow / net income0.53x
Accruals ratio8.2%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$4.15B$2.19B$1.19B$400.72M$497.28M
Cost of revenue$450.67M$227.29M$117.83M$29.43M—
Gross profit$3.70B$1.96B$1.07B$371.29M—
R&D expense$1.36B$983.42M$859.49M$663.37M$580.52M
SG&A expense$1.37B$1.06B$711.90M$472.13M$307.64M
Operating income$1.05B-$21.65M-$425.05M-$720.34M-$348.75M
Interest expense$4.08M$2.46M$906,000$3.91M$4.58M
Pretax income$1.28B$85.18M-$304.50M-$729.31M-$399.74M
Income tax-$13.43M-$747.86M-$9.44M-$19.72M$8.52M
Net income$1.29B$833.04M-$295.05M-$709.59M-$408.26M
EPS (basic)21.0813.92-5.16-13.05-7.99
EPS (diluted)19.5712.78-5.16-13.05-7.99
Weighted avg. shares (diluted)66.03M65.18M57.17M54.38M—
Balance sheet
Cash & equivalents$3.49B$1.50B$2.05B$800.74M$1.33B
Receivables$1.65B$904.47M$496.69M$275.70M$38.22M
Inventory$473.53M$407.23M$310.55M$228.35M$109.08M
Current assets$6.90B$4.88B$4.12B$2.77B$2.54B
PP&E, netmay include right-of-use assets (IFRS)$48.25M$43.52M$22.68M$16.23M$15.84M
Intangibles$272.10M$181.44M$125.23M$174.90M$171.68M
Total assets$8.68B$6.20B$4.54B$3.13B$2.85B
Current liabilities$1.32B$669.92M$422.99M$302.28M$301.24M
Total liabilities$1.36B$704.24M$444.95M$320.56M$316.05M
Shareholders' equity$7.32B$5.50B$4.10B$2.81B$2.53B
Shares outstanding61.88M60.76M59.19M55.40M51.67M
Cash flow statement
Operating cash flow$685.19M-$82.75M-$420.33M-$862.81M-$606.81M
Capital expenditure$6.17M$1.80M$812,000$837,000$3.62M
Free cash flow$679.03M-$84.55M-$421.14M-$863.64M-$610.43M
Investing cash flow$984.00M-$717.59M$308.21M-$461.18M-$347.07M
Financing cash flow$233.01M$279.76M$1.34B$843.76M$1.12B
Stock-based compensation$248.08M$235.18M$232.97M$157.03M$179.37M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.